October 18, 2011

Sanofi and its subsidiary Genzyme to Feature More than 20 Data Presentations at the ECTRIMS/ACTRIMS Congress

Depth of Research, Including Pivotal Phase III Data for LemtradaTM* and AubagioTM*, Underscores Genzyme’s Commitment to Patients with Multiple Sclerosis -

 

Sanofi and its subsidiary Genzyme to Feature More than 20 Data Presentations at the ECTRIMS/ACTRIMS Congress
Depth of Research, Including Pivotal Phase III Data for LemtradaTM* and AubagioTM*, Underscores Genzyme’s Commitment to Patients with Multiple Sclerosis -

Paris, France – October 18, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that more than 20 data presentations from the company’s growing multiple sclerosis (MS) portfolio will be showcased at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS 2011). Data to be presented will include new results from pivotal Phase III clinical trials of the company’s lead investigational candidates for the treatment of relapsing MS, LemtradaTM (alemtuzumab) and AubagioTM (oral teriflunomide), and will be featured in platform and poster presentations.